Comparison · NCT00790868-sae
D-cycloserine vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. D-cycloserine vs Placebo: serious adverse events. Trial comparisons, record NCT00790868-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00790868-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0114 | 0.00201 | 0.0616 | wilson | |
| Risk in group 2 | 0.0109 | 0.00192 | 0.059 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000494 | -0.0486 | 0.0515 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.0664 | 16.5 | log | |
| Odds ratio, group 1 over group 2 | 1.05 | 0.0644 | 17 | log | |
| Number needed to harm, for one more participant with a serious adverse event on D-cycloserine than on Placebo | 2,020 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | D-cycloserine | DCS-augmented CBT~D-cycloserine: 50mg | 1 | 88 | EG000 |
| Group 2 | Placebo | Placebo-augmented CBT~Placebo: 50mg | 1 | 92 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse events were monitored and elicited by open questioning of the study clinician, assessing adverse events occurring over the last hour as well as during the week following the last dose of DCS. AEs and SAEs were informally assessed up to the 6-month follow-up.
Source ClinicalTrials.gov
Trial
- Title
- Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder
- NCT number
- NCT00790868
- Phases
- PHASE2
- Conditions
- Panic Disorder
- Interventions
- d-cycloserine, placebo
- Lead sponsor
- Boston University Charles River Campus
- Results first posted
- 2018-03-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00790868?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00790868-sae